Lawsuit filed against makers of Ozempic and Mounjaro l GMA
In a surprising turn of events, the manufacturers of the widely-used weight loss drugs Ozempic and Manjaro find themselves entangled in a legal battle. These diabetes medications, known for their slimming side effects, have gained immense popularity amongst individuals looking to shed those extra pounds. However, a new lawsuit alleges that these drugs may also have dangerous side effects that have not been adequately disclosed.
The demand for Ozempic and Manjaro has skyrocketed as people have shared their success stories using these drugs, which are primarily meant for treating type 2 diabetes but are often prescribed off-label for weight loss. In the lawsuit, a woman claims to have lost an impressive 150 pounds, but argues that the manufacturers failed to sufficiently warn about the risk of gastroparesis – a condition characterized by the slowing or stopping of food movement in the stomach. Although she hasn’t received an official diagnosis, her severe problems have forced her to visit the emergency room multiple times, including just last weekend.
Dr. Darian Sutton, a medical contributor for ABC News, explains that while isolated cases of stomach paralysis have been observed, no large-scale studies have confirmed this effect. Nonetheless, the consequences can be severe, with patients suffering from dehydration, electrolyte imbalances, and symptoms that are difficult to control, often requiring hospitalization.
The drug labels do include warnings about side effects such as nausea and vomiting, as well as a cautionary note about delayed gastric emptying. The manufacturers maintain that the medication has undergone extensive study, with Novo Nordisk, the maker of Ozempic, stating that gastrointestinal events are well-known side effects, primarily mild to moderate and of short duration. Eli Lilly, the manufacturer of Manjaro, affirms their commitment to monitoring and reporting safety information for all their medicines.
Interestingly, this legal battle emerges amidst reports that many employers are ceasing to provide insurance coverage for similar weight loss drugs due to their exorbitant costs, which can exceed $1,300 per month. This decision is reportedly straining employer-funded healthcare plans, and it remains to be seen how this will impact the popularity of these drugs.
It is evident that this lawsuit has raised important questions regarding the potential side effects of Ozempic and Manjaro. As the legal battle unfolds, the manufacturers will undoubtedly face scrutiny over their responsibility to adequately warn consumers about potential risks associated with their products. Meanwhile, individuals seeking weight loss solutions may need to consider the financial implications of these medications, given the increasing challenges in obtaining insurance coverage for them.